Oxaliplatin‑induced changes in splenic volume and liver fibrosis indices: retrospective analyses of colon cancer patients receiving adjuvant chemotherapy

References

• André T, Boni C, Mounedji-Boudiaf L, et al. Multicenter ınternational study of oxaliplatin/5-Fluorouracil/leucovorin in the adjuvant treatment of Colon cancer (MOSAIC) ınvestigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for Colon cancer. N Engl J Med. 2004;350(23):2343–2351. doi: 10.1056/NEJMoa032709.
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III Colon cancer. J Clin Oncol. 2011;29(11):1465–1471. doi: 10.1200/JCO.2010.33.6297.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cartwright T, Tabernero J, et al. Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III Colon cancer: a planned safety analysis in 1,864 patients. J Clin Oncol. 2007;25(1):102–109. doi: 10.1200/JCO.2006.08.1075.
   PubMed Web of Science ®Google Scholar
• Saez-Carlin P, García-Botella A, Diez-Valladares LI, et al. Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM). Clin Transl Oncol. 2020;22(7):1180–1186. doi: 10.1007/s12094-019-02245-1.
   PubMed Web of Science ®Google Scholar
• Iwai T, Yamada T, Koizumi M, et al. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX. J Surg Oncol. 2017;116(7):947–953. doi: 10.1002/jso.24756.
   PubMed Web of Science ®Google Scholar
• Vreuls CP, Van Den Broek MA, Winstanley A, et al. Hepatic sinusoidal obstruction syndrome (SOS) reduces the effect of oxaliplatin in colorectal liver metastases. Histopathology. 2012;61(2):314–318. doi: 10.1111/j.1365-2559.2012.04208.x.
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Glimelius B, et al. EORTC Gastro-Intestinal Tract Cancer Group; Cancer Research UK; arbeitsgruppe lebermetastasen und-tumoren in der chirurgischen arbeitsgemeinschaft onkologie (ALM-CAO); Australasian Gastro-Intestinal trials group (AGITG); fédération francophone de cancérologie digestive (FFCD). Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC ıntergroup trial 40983): a randomised controlled trial. Lancet. 2008;371(9617):1007–1016. doi: 10.1016/S0140-6736(08)60455-9.
   PubMed Web of Science ®Google Scholar
• Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247(1):118–124. doi: 10.1097/SLA.0b013e31815774de.
   PubMed Web of Science ®Google Scholar
• Ward J, Guthrie JA, Sheridan MB, et al. Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol. 2008;26(26):4304–4310. doi: 10.1200/JCO.2008.16.1893.
   PubMed Web of Science ®Google Scholar
• O'Rourke TR, Welsh FK, Tekkis PP, et al. Accuracy of liver-specific magnetic resonance imaging as a predictor of chemotherapy-associated hepatic cellular injury prior to liver resection. Eur J Surg Oncol. 2009;35(10):1085–1091. doi: 10.1016/j.ejso.2009.01.015.
   PubMed Web of Science ®Google Scholar
• Imai K, Emi Y, Iyama KI, Kyusyu Study Group of Clinical Cancer (KSCC) Ancillary Study, et al. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol. 2014;40(5):559–566. doi: 10.1016/j.ejso.2013.12.009.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Maru DM, Charnsangavej C, et al. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol. 2010;28(15):2549–2555. doi: 10.1200/JCO.2009.27.5701.
   PubMed Web of Science ®Google Scholar
• Lind L, Johansson L, Ahlström H, et al. Comparison of four non-alcoholic fatty liver disease detection scores in a Caucasian population. World J Hepatol. 2020;12(4):149–159. doi: 10.4254/wjh.v12.i4.149.
   PubMed Web of Science ®Google Scholar
• Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525–540. doi: 10.1111/j.1365-2036.2010.04556.x.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. Obes Facts. 2016;9(2):65–90.
   PubMed Web of Science ®Google Scholar
• Contreras D, González-Rocha A, Clark P, et al. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: systematic review and meta-analysis. Ann Hepatol. 2023;28(1):100873. doi: 10.1016/j.aohep.2022.100873.
   PubMed Web of Science ®Google Scholar
• Srivastava A, Gailer R, Tanwar S, et al. Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease. J Hepatol. 2019;71(2):371–378. doi: 10.1016/j.jhep.2019.03.033.
   PubMed Web of Science ®Google Scholar
• Sonneveld MJ, Brouwer WP, Chan HL, et al. Optimisation of the use of APRI and FIB-4 to rule out cirrhosis in patients with chronic hepatitis B: results from the SONIC-B study. Lancet Gastroenterol Hepatol. 2019;4(7):538–544. doi: 10.1016/S2468-1253(19)30087-1.
   PubMed Web of Science ®Google Scholar
• Prassopoulos P, Daskalogiannaki M, Raissaki M, et al. Determination of normal splenic volume on computed tomography in relation to age, gender and body habitus. Eur Radiol. 1997;7(2):246–248. doi: 10.1007/s003300050145.
   PubMed Web of Science ®Google Scholar
• Ji R, Huang G, Xu J, et al. Splenomegaly during oxaliplatin-based chemotherapy: impact on blood parameters and anti-neoplastic treatment. Transl Cancer Res. 2022;11(7):1880–1888. doi: 10.21037/tcr-22-83.
   PubMed Web of Science ®Google Scholar
• Miyata T, Takamura H, Kin R, et al. Spleen volume as a predictive biomarker for thrombocytopenia and liver dysfunction after oxaliplatin-based chemotherapy. Anticancer Res. 2020;40(6):3361–3370. doi: 10.21873/anticanres.14319.
   PubMed Web of Science ®Google Scholar
• Laurent A, Nicco C, Chéreau C, et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 2005;65(3):948–956. doi: 10.1158/0008-5472.948.65.3.
   PubMed Web of Science ®Google Scholar
• Alexandre J, Nicco C, Chéreau C, et al. Improvement of the therapeutic index of anticancer drugs by the superoxide dismutase mimic mangafodipir. J Natl Cancer Inst. 2006;98(4):236–244. doi: 10.1093/jnci/djj049.
   PubMedGoogle Scholar
• Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460–466. doi: 10.1093/annonc/mdh095.
   PubMed Web of Science ®Google Scholar
• El Chediak A, Haydar AA, Hakim A, et al. Increase in spleen volume as a predictor of oxaliplatin toxicity. Ther Clin Risk Manag. 2018;14:653–657. doi: 10.2147/TCRM.S150968.
   PubMed Web of Science ®Google Scholar
• Jung EJ, Ryu CG, Kim G, et al. Splenomegaly during oxaliplatin-based chemotherapy for colorectal carcinoma. Anticancer Res. 2012;32(8):3357–3362.
   PubMed Web of Science ®Google Scholar
• Miura K, Nakano H, Sakurai J, et al. Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol. 2011;16(3):257–263. doi: 10.1007/s10147-010-0176-0.
   PubMed Web of Science ®Google Scholar
• Park S, Kim HY, Kim H, et al. Changes in noninvasive liver fibrosis ındices and spleen size during chemotherapy: potential markers for oxaliplatin-ınduced sinusoidal obstruction syndrome. Medicine (Baltimore). 2016;95(2):e2454. doi: 10.1097/MD.0000000000002454.
   PubMed Web of Science ®Google Scholar
• Mukai K, Nishida T, Matsumoto K, et al. Predictive factors of collateral vessel development induced by oxaliplatin-based chemotherapy. Int J Clin Oncol. 2023;28(2):280–288. doi: 10.1007/s10147-022-02280-z.
   PubMed Web of Science ®Google Scholar
• Tajima H, Ohta T, Miyashita T, et al. Oxaliplatin-based chemotherapy induces extravasated platelet aggregation in the liver. Mol Clin Oncol. 2015;3(3):555–558. doi: 10.3892/mco.2015.512.
   PubMedGoogle Scholar
• Lee VH, Fang WJ, Lam KO, et al. Impact of CAPOX or FOLFOX4 on spleen size, platelet count and liver function when partnered cetuximab as first-line treatment for KRAS wild-type metastatic colorectal cancer. Cancer Res Front. 2015;1(1):60–74. doi: 10.17980/2015.60.
   Google Scholar
• Chin SN, Kim TK, Siu LL. Hepatic steatosis secondary to capecitabine: a case report. J Med Case Rep. 2010;4:227.
   PubMedGoogle Scholar
• Groom K, Penna M, Arul D, et al. Capecitabine-related liver lesions: sinusoidal dilatation mimicking liver metastasis. Clin Case Rep. 2016;4(6):545–548. doi: 10.1002/ccr3.539.
   PubMedGoogle Scholar
• Kim MJ, Han SW, Lee DW, et al. Splenomegaly and ıts associations with genetic polymorphisms and treatment outcome in colorectal cancer patients treated with adjuvant FOLFOX. Cancer Res Treat. 2016;48(3):990–997. doi: 10.4143/crt.2015.296.
   PubMed Web of Science ®Google Scholar